Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors - PubMed (original) (raw)
. 2015 Dec;3(12):1344-55.
doi: 10.1158/2326-6066.CIR-15-0097. Epub 2015 Aug 7.
Jens Schreiner 2, Philipp Müller 2, Petra Herzig 2, Andreas Roller 3, Anton Belousov 3, Pablo Umana 4, Pavel Pisa 4, Christian Klein 4, Marina Bacac 4, Ozana S Fischer 5, Wolfgang Moersig 5, Spasenija Savic Prince 6, Victor Levitsky 4, Vaios Karanikas 4, Didier Lardinois 5, Alfred Zippelius 1
Affiliations
- PMID: 26253731
- DOI: 10.1158/2326-6066.CIR-15-0097
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S Thommen et al. Cancer Immunol Res. 2015 Dec.
Abstract
Dysfunctional T cells present in malignant lesions are characterized by a sustained and highly diverse expression of inhibitory receptors, also referred to as immune checkpoints. Yet, their relative functional significance in different cancer types remains incompletely understood. In this study, we provide a comprehensive characterization of the diversity and expression patterns of inhibitory receptors on tumor-infiltrating T cells from patients with non-small cell lung cancer. In spite of the large heterogeneity observed in the amount of PD-1, Tim-3, CTLA-4, LAG-3, and BTLA expressed on intratumoral CD8(+) T cells from 32 patients, a clear correlation was established between increased expression of these inhibitory coreceptors and progression of the disease. Notably, the latter was accompanied by a progressively impaired capacity of T cells to respond to polyclonal activation. Coexpression of several inhibitory receptors was gradually acquired, with early PD-1 and late LAG-3/BTLA expression. PD-1 blockade was able to restore T-cell function only in a subset of patients. A high percentage of PD-1(hi) T cells was correlated with poor restoration of T-cell function upon PD-1 blockade. Of note, PD-1(hi) expression marked a particularly dysfunctional T-cell subset characterized by coexpression of multiple inhibitory receptors and thus may assist in identifying patients likely to respond to inhibitory receptor-specific antibodies. Overall, these data may provide a framework for future personalized T-cell-based therapies aiming at restoration of tumor-infiltrating lymphocyte effector functions.
©2015 American Association for Cancer Research.
Similar articles
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J. Zhou G, et al. Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23. Gastroenterology. 2017. PMID: 28648905 - Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Datar I, et al. Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3. Clin Cancer Res. 2019. PMID: 31053602 Free PMC article. - PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C. Zelba H, et al. Cancer Immunol Res. 2019 Nov;7(11):1891-1899. doi: 10.1158/2326-6066.CIR-19-0146. Epub 2019 Sep 4. Cancer Immunol Res. 2019. PMID: 31484656 - Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Anderson AC, Joller N, Kuchroo VK. Anderson AC, et al. Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001. Immunity. 2016. PMID: 27192565 Free PMC article. Review. - Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. De Sousa Linhares A, et al. Front Immunol. 2018 Aug 31;9:1909. doi: 10.3389/fimmu.2018.01909. eCollection 2018. Front Immunol. 2018. PMID: 30233564 Free PMC article. Review.
Cited by
- Exploring the molecular landscape of lymphocyte activation gene-3: A literature review.
Nie J, Qin X, Tao X, Huang J. Nie J, et al. Medicine (Baltimore). 2024 Sep 27;103(39):e39622. doi: 10.1097/MD.0000000000039622. Medicine (Baltimore). 2024. PMID: 39331884 Free PMC article. Review. - Solid tumour-induced systemic immunosuppression involves dichotomous myeloid-B cell interactions.
Hao X, Shen Y, Liu J, Alexander A, Wu L, Xu Z, Yu L, Gao Y, Liu F, Chan HL, Li CH, Ding Y, Zhang W, Edwards DG, Chen N, Nasrazadani A, Ueno NT, Lim B, Zhang XH. Hao X, et al. Nat Cell Biol. 2024 Sep 12. doi: 10.1038/s41556-024-01508-6. Online ahead of print. Nat Cell Biol. 2024. PMID: 39266726 - Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble.
Chang X, Miao J. Chang X, et al. Front Immunol. 2024 Aug 13;15:1407403. doi: 10.3389/fimmu.2024.1407403. eCollection 2024. Front Immunol. 2024. PMID: 39206199 Free PMC article. Review. - Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer.
Reyes A, Muddasani R, Massarelli E. Reyes A, et al. Cancers (Basel). 2024 Aug 22;16(16):2919. doi: 10.3390/cancers16162919. Cancers (Basel). 2024. PMID: 39199689 Free PMC article. Review. - Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma.
Yuan P, Long Y, Wei N, Wang Y, Zhu Z, Han J, Jiang D, Lan X, Gai Y. Yuan P, et al. J Immunother Cancer. 2024 Jul 23;12(7):e009010. doi: 10.1136/jitc-2024-009010. J Immunother Cancer. 2024. PMID: 39043603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials